Examkin

Soru

Zorluk: OrtaDepressive Disorders

A 42-year-old woman is evaluated in the psychiatric clinic and diagnosed with a moderate major depressive episode without psychotic features. Over the next 18 months, she requires multiple adjustments to her treatment plan due to inadequate symptom relief. Ultimately, her condition deteriorates, and she develops severe psychotic depression with delusions of guilt and total refusal to consume food or fluids. According to standard clinical guidelines for the stepped-care management of major depressive disorder, arrange the following therapeutic interventions in the most appropriate chronological sequence of escalation.

  1. 1Initiate monotherapy with a selective serotonin reuptake inhibitor (e.g., sertraline)
  2. 2Switch to a different class of antidepressant (e.g., a serotonin-norepinephrine reuptake inhibitor) following an adequate trial without response
  3. 3Augment the current antidepressant regimen with an atypical antipsychotic (e.g., aripiprazole) to target a partial response
  4. 4Admit for inpatient psychiatric care and prepare to administer electroconvulsive therapy (ECT)

Cevap

The correct sequence of treatment escalation begins with initiating SSRI monotherapy, followed by switching to an SNRI after an initial non-response, then augmenting with an atypical antipsychotic for partial response, and finally utilizing electroconvulsive therapy (ECT) when the patient develops life-threatening psychotic features and food refusal.
The management of major depressive disorder (MDD) follows a sequential, stepped-care model based on treatment response and symptom severity. For a newly diagnosed, uncomplicated episode, first-line treatment is SSRI monotherapy. If an adequate trial (typically 4-8 weeks at a therapeutic dose) yields no significant improvement, standard guidelines recommend switching to another first-line antidepressant, such as an SNRI or a different SSRI. If a subsequent trial yields a partial response, the addition of an augmenting agent (e.g., an atypical antipsychotic, lithium, or triiodothyronine) is indicated to boost efficacy. Finally, if the patient's condition continues to worsen and they develop life-threatening symptoms—such as psychotic features (delusions/hallucinations), severe suicidality, or refusal to eat and drink—electroconvulsive therapy (ECT) becomes the most urgent and effective treatment of choice.

Adım Adım Çözüm

1
Determine the first-line pharmacotherapy for an initial diagnosis of unipolar major depressive disorder.
Initiation of SSRI monotherapy.
SSRIs have a favorable side-effect profile and are the gold standard for initiating MDD treatment.
2
Identify the standard clinical step when a patient exhibits minimal to no response after an adequate SSRI trial (4-8 weeks).
Switching to a different antidepressant (e.g., an SNRI).
Switching monotherapy is preferred over early polypharmacy when the initial agent provides virtually no benefit.
3
Determine the appropriate intervention when a patient achieves only a partial response to a subsequent antidepressant trial.
Augmentation of the current regimen with an evidence-based adjunct (e.g., an atypical antipsychotic).
Augmentation maximizes the partial benefit already achieved by the current antidepressant while minimizing the risk of losing that progress by switching again.
4
Identify the primary indication for electroconvulsive therapy (ECT) in the context of progressive clinical deterioration.
Admission and administration of ECT.
The development of psychotic features and refusal to eat or drink constitutes a psychiatric emergency requiring the rapid, definitive efficacy provided by ECT.

Anahtar Kavram

Stepped-care pharmacological escalation and indications for electroconvulsive therapy in major depressive disorder
Bu soruyu puanla

Konular

Depressive Disorders

Bu konudan daha fazla soru